Latest News and Press Releases

Company announcement – No. 39 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, November 16, 2023 – Zealand Pharma...

Company announcement - No. 38 / 2023 Zealand Pharma Announces Financial Results for the First Nine Months of 2023 Strong progress across obesity pipeline, first PDUFA date for...

Press release – No. 15 / 2023 Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023 Copenhagen, Denmark, November 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...

Press Release – No. 14 / 2023 Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results Copenhagen, Denmark, November 3, 2023 – a Zealand...

Company announcement – No. 37 / 2023 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 20 October 2023 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20...

Press release – No. 13 / 2023 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek Copenhagen, Denmark, October 17, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no....

Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease Press release – No. 12 /...

Company announcement – No. 36 / 2023 Total number of shares and voting rights in Zealand Pharma at September 29, 2023 Copenhagen, Denmark, September 29, 2023 – Zealand Pharma A/S (“Zealand”)...

Company announcement – No. 35 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 34 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 14, 2023 – Zealand Pharma A/S...